| Previous close | 2.16 |
| Open | 2.20 |
| Day's range | 1.61 to 2.22 |
| 52-week range | 1.35 to 3.58 |
| Volume | 349.8K |
| Average volume (3 months) | 166.8K |
| 1-year price change | -38.11% |
| Market value | 11.88M |
| Beta (1 year) | 1.78 |
| Dividend yield | None |
Company figures come from SEC filings through the quarter ending Jun 30, 2025. All statistics
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
For learning only, not investment advice. Chart by TradingView. How to read a stock quote.